Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

著者: Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n, B. Yа. Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe, Giri Sulur, Yesenia Luna, Susan Li, Suneel Mundle, Kim N. - The Lancet 2019 被引用: 813